Emris Pharma
Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients
Company Overview
Snapshot
Founded in May 2023 by Lyora Aharonov, Emris Pharma operates with 1–10 employees. The company has secured funding across one round from two investors, with NGT HealthCare II identified as a lead investor. In May 2023, Emris Pharma launched the development of a novel topical drug aimed at preventing skin toxicities induced by EGFR inhibitors.
Business overview
Emris Pharma is a Health Tech & Life Sciences company focused on developing innovative solutions for cancer patients. The company's core product, SDT 011 (EMR-001), is a novel small molecule topically administered to prevent skin toxicities caused by EGFR inhibitors. This therapy aims to improve the quality of life for cancer patients and enhance compliance with their treatment. Emris Pharma operates within the pharmaceuticals, cancer, and skin care sectors, targeting a global market with unmet needs, particularly as new combinations of cancer treatments with EGFRi and bi-specific antibodies emerge.
Strategic signal
In May 2023, Emris Pharma, a spin-off of Hadasit and Yissum, launched the development of a new innovative topical drug for the treatment of skin toxicities. This development signals a significant advancement in supportive cancer care, addressing a critical unmet need for patients undergoing EGFR inhibitor therapies. For investors, this highlights the company's potential to capture a substantial market share by improving patient quality of life and treatment adherence, thereby validating its early-stage strategic direction and product pipeline.
Company Intelligence Q&A
- When was Emris Pharma founded?
- Emris Pharma was founded in May 2023.
- Who are the founders of Emris Pharma?
- Lyora Aharonov is a co-founder and CEO of Emris Pharma.
- What is Emris Pharma's primary focus?
- Emris Pharma focuses on developing a novel small molecule topically administered for the prevention of skin toxicities induced by EGFR inhibitors, aiming to improve cancer patients’ quality of life and compliance with cancer therapy.
- What was a key development for Emris Pharma in 2023?
- In May 2023, Emris Pharma launched the development of a new innovative topical drug for the treatment of skin toxicities, improving treatment and quality of life for cancer patients.
- Which investors participated in Emris Pharma's funding round?
- Emris Pharma received funding from NGT HealthCare II and Israel Innovation Authority in May 2023.